Drug Database
BU

budesonide (budesonide Modulite / budesonide, Chiesi / budesonide Modulite)

✓ Approved

Chiesi Farmaceutici S.p.A. · NR3C1 · 小分子

什么是 budesonide?

budesonide 是一种小分子,由Chiesi Farmaceutici S.p.A.研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled、Topical。

药物档案

商品名budesonide Modulite, budesonide, Chiesi, budesonide Modulite
公司Chiesi Farmaceutici S.p.A.
药物类别小分子
分子靶点NR3C1
给药途径Inhaled, Topical
状态Approved

作用机制

分子靶点

budesonide 作用于 1 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

budesonide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

相关研究文献

PubMedCJC open2026-11-17

Likelihood and Outcomes of Heart Failure With Nonreduced Ejection Fraction Among Patients With Negative Cardiac Amyloidosis Screening.

Dal Soglio Solenn S, Beaulieu Marie-Claude MC, Lucinian Yousif A YA, Moazzami Chloé C et al.

Heart failure with nonreduced ejection fraction (HFnrEF) is a clinically heterogeneous condition leading to diagnostic challenges. Identifying populations with a higher likelihood of HFnrEF may increase diagnostic efficiency and translate into earlier appropriate care. We conducted a retrospective cohort analysis of adult patients with a left ventricular ejection fraction ≥ 40% and negative CA screening (pyrophosphate single-photon emission computed tomography imaging and/or via a dedicated cardiac amyloidosis [CA] clinic) at our center from January 2018 to August 2023. H2FPEF and HFA-PEFF scores were calculated for each patient. Patients were subsequently categorized as high (both H2FPEF ≥ 6 and HFA-PEFF ≥ 5), intermediate (either H2FPEF ≥ 6 or HFA-PEFF ≥ 5), or otherwise indeterminate probability of HFnrEF. Baseline medical management and clinical outcomes at 1 year were recorded. Of the 302 patients included (43% women, mean age 74 years, body mass index 28.7 ± 6.8 kg/m2, N-terminal prohormone brain natriuretic peptide level 4640 ± 7877 ng/L), 25% were classified as high and 42% as intermediate HFnrEF probability. However, only half had a documented clinical diagnosis of HFnrEF. Among patients with high or intermediate probability, 6% were treated with sodium glucose transporter-2 inhibitors, 29% with mineralocorticoid receptor antagonists, and 43% with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. At 1-year follow-up, the heart failure hospitalization rate was 16% and mortality was 14% in this group. Two thirds of patients with negative CA screening had intermediate or high probability of HFnrEF based on H2FPEF and HFA-PEFF scores, which was also associated with a higher rate of adverse events. Using these scores in combination to prioritize patient referrals to dedicated HFnrEF clinics may lead to improved treatment and outcomes.

PMID 43042256
阅读全文 →
PubMedJournal of pediatric gastroenterology and nutrition2026-11-17

Standardizing the slurry: International Dysphagia Diet Standardization Initiative testing of budesonide formulations for eosinophilic esophagitis.

Syverson Erin P EP, Hait Elizabeth E, IDDSI EoE Formulation Study Group

PMID 43042590
阅读全文 →
PubMedCureus2026-11-17

Global Convergence and Divergence in Clinical Practice Guidelines for Heart Failure With Preserved Ejection Fraction: A Systematic Comparative Review.

Dunkwu Caleb C CC, Bashir Isha I, Erhieyovwe Emmanuel E, Aghale Oghenekome S OS

Heart failure with preserved ejection fraction (HFpEF) is a growing global health challenge, yet international clinical guidance remains heterogeneous. This review synthesizes HFpEF recommendations from major national and international guidelines published between 2014 and March 2026. A systematic, PRISMA-informed search of bibliographic databases, guideline repositories, and professional society websites identified 1,061 records. Following deduplication and two-stage screening, 15 distinct documents met the eligibility criteria, spanning Europe, North America, South America, Asia, and Oceania. Data were extracted on diagnostic criteria, natriuretic peptide thresholds, scoring systems, pharmacological and nonpharmacological management, comorbidity strategies, and follow-up recommendations. Methodological quality was appraised using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument, and findings were synthesized narratively. Regional endorsement and adaptation frameworks, specifically those from the Pan-African Society of Cardiology (PASCAR), were integrated via qualitative synthesis. There was strong global consensus on the core diagnostic definition of HFpEF, the role of natriuretic peptides and echocardiography, the use of diuretics for congestion, and sodium-glucose cotransporter 2 (SGLT2) inhibitors as foundational disease-modifying therapy. Variation persisted in diagnostic scoring systems (HFA-PEFF vs. H₂FPEF vs. none), natriuretic peptide thresholds (particularly those recommended by the National Institute for Health and Care Excellence (NICE)), use of advanced diagnostic testing, and phenotype-specific recommendations. The 2023 Saudi Heart Association update strengthened representation from the Middle East, with regional emphasis on diabetes, obesity, and metabolic syndrome. No sub-Saharan African guideline was identified; the PASCAR provides capacity-building frameworks rather than formal recommendation-based guidance. This review provides a comprehensive comparative analysis of contemporary HFpEF guidelines. Findings highlight increasing international convergence, particularly following recent Japanese and Saudi updates, alongside persistent diagnostic and therapeutic divergence that may influence clinical practice and equity of care. The absence of region-specific HFpEF guidance in Africa represents a key gap. Greater harmonization of diagnostic pathways, wider adoption of validated scoring systems, and improved contextualization of management across diverse health systems are needed.

PMID 43042174
阅读全文 →
PubMedJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2026-11-16

Hypoglossal-facial nerve anastomosis for facial nerve injury after vestibular schwannoma surgery: A systematic review and meta-analysis.

Cua Sean Kendrich N SKN, Pascual Juan Silvestre G JSG, Khu Kathleen Joy O KJO

Facial nerve injury is one of the most common and distressing complications following vestibular schwannoma (VS) surgery. Hypoglossal-facial nerve anastomosis (HFA) is a nerve repair technique used in patients with facial nerve injury. This systematic review and meta-analysis aimed to evaluate the techniques, outcomes, and complications of HFA for facial nerve injury following VS resection. A systematic search of PubMed, Embase, Scopus, and Herdin databases was conducted from inception to September 2025. Studies were included if they reported HFA for facial nerve injury after VS surgery. Data on patient demographics, interval between injury and HFA, surgical techniques, outcomes, complications, and follow-up duration were obtained. A meta-analysis of comparative studies was performed using RevMan software. Forty-eight studies comprising 866 VS patients were included. The mean age ranged from 35.4 to 56.3 years. The most frequently reported HFA technique was end-to-end, followed by side-to-end, hemihypoglossal-facial anastomosis, and dual nerve transfer (HFA + masseter-facial anastomosis). 91.0% of patients demonstrated improvement in facial function; 46.4% achieved House-Brackmann grade III or better. Meta-analysis conducted on four studies showed significantly greater odds of favorable outcome after HFA versus conservative treatment (OR 6.42, 95% CI 1.74-23.65; p = 0.005). Complications included tongue hemiatrophy (22.5%), eating difficulty (17.0%), synkinesis (14.1%), and speech disarticulation (8.3%). Our review showed that HFA improved the facial nerve function of patients with facial nerve injury after resection of VS, but this procedure carried a notable risk of complications, particularly tongue hemiatrophy.

PMID 43035053
阅读全文 →
PubMedCardiology journal2026-11-16

Clinical characteristics of outpatients with HFpEF and HFmrEF at a cardiology clinic in Poland: a 2025 cross-sectional study.

Szychta Wojciech W, Filipiak Krzysztof J KJ

Chronic heart failure is a highly prevalent condition in aging populations. In Poland, it is estimated to affect approximately 1.2 million individuals, with a substantial number of cases being misdiagnosed, partly due to the presence of comorbidities. This cross-sectional, single-center study aimed to collect real-world data on ambulatory patients diagnosed with either heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF). Patients were screened for eligibility during routine outpatient visits using an integrated diagnostic pathway consistent with the Heart Failure Association's HFA-PEFF algorithm. Data included patient demographics, clinical characteristics, cardiovascular parameters, comorbidities, and pharmacotherapy. A total of 500 patients were included; nearly 70% were women. HFpEF was diagnosed in 75.6% of patients, whereas HFmrEF was identified in 24.4%. Most patients had hypertension (84.8%) and peripheral arterial disease (77.4%); and 23.8% of patients had type 2 diabetes. The mean left atrial volume index (LAVI) was 44.9 ± 19.1 mL/m2, and the mean E/e' ratio was 13.8 ± 5.4. Reduced renal function (eGFR < 60 mL/min/1.73 m2) was observed in 42% of patients. All participants received combination pharmacotherapy, most commonly finerenone (98.8%), beta-blockers (82.8%), and sodium-glucose cotransporter 2 inhibitors (SGLT2is) (98.6%); over half of all participants (59.8%) were treated with loop diuretics. The study provides valuable real-world data on patients with chronic heart failure at a single outpatient cardiology clinic in Poland, highlighting a predominance of the HFpEF phenotype, which is consistent with recent trends in heart failure diagnosis.

PMID 43037157
阅读全文 →
PubMedClinical kidney journal2026-11-15

Portal vein thrombosis following targeted-release budesonide in IgA nephropathy and occult liver disease.

Braun Gerald S GS, Seikrit Claudia C

Targeted-release budesonide (Nefecon) is the first gut-kidney axis-directed therapy for high-risk immunoglobulin A nephropathy (IgAN) and relies on intact hepatic first-pass metabolism to limit systemic exposure. We report a 63-year-old man who developed acute portal vein thrombosis within 3 days of treatment initiation. Imaging demonstrated near-complete thrombosis of the portal venous system. Subsequent evaluation revealed previously unrecognized chronic liver disease, including hereditary hemochromatosis, alcohol use, and early hepatocellular carcinoma without vascular invasion. In conjunction with three previously reported cases of splanchnic vein thrombosis in patients receiving budesonide to treat advanced autoimmune hepatobiliary disease and published pharmacokinetic data, this observation suggests that hepatic dysfunction and disease may lower the thrombotic threshold for budesonide. These findings support careful assessment of hepatic function when initiating targeted-release budesonide in IgAN.

PMID 43032333
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多budesonide